Polymorphism of peroxisome proliferator-activated receptor gamma is not associated to Japanese ulcerative colitis

Hepato-Gastroenterology

Volumn 55, Issue 81, 2008, Pages 73-75

  Wang, Fangyu ^a,b   Tahara, Tomomitsu ^a   Arisawa, Tomiyasu ^a   Sakata, Mikijyu ^a   Takahama, Kazuya ^a   Watanabe, Makoto ^a   Hirata, Ichiro ^a   Nakano, Hiroshi ^a  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NONE   (Japan)

Author keywords

Peroxisome proliferator activated receptor gamma (PPARy); Polymorphism; Ulcerative colitis (UC)

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADULT; AGED; ARTICLE; CONFIDENCE INTERVAL; CONTROL GROUP; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FISHER EXACT TEST; GENE; GENOTYPE; HETEROZYGOTE; HUMAN; HUMAN TISSUE; JAPANESE; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; POLYMERASE CHAIN REACTION; POPULATION; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; RISK; ULCERATIVE COLITIS;

ADULT; COLITIS, ULCERATIVE; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PPAR GAMMA;

EID: 41549121910     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Podolsky DK: Inflammatory bowel disease. N Engl J Med 2002; 347:417-429.
2. Sakamoto N, Kono S, Wakai K, Fukuda Y, Satomi M, Shimoyama, Inaba Y, Miyake Y, Sakai S, Okamoto K, Kobashi G, Washio M, Yokoyama T, Date C, Tanaka H: Epidemiology Group of the Research Committee on Inflammatory Bowel Disease in Japan: Dietary risk factors for inflammatory bowel disease: a multicenter case-control study in Japan. Inflamm Bowel Dis 2005; 11:154-163.
3. Tanaka M, Kazuma K: Ulcerative colitis: factors affecting difficulties of life and psychological well being of patients in remission. J Clin Nurs 2005; 14:65-73.
4. Newman B, Siminovitch KA: Recent advances in the genetics of inflammatory bowel disease. Curr Opin Gastroenterol 2005; 21:401-407.
5. Bonen DK, Cho JH: The genetics of inflammatory bowel disease. Gastroenterology 2003; 124:521-536.
6. Dubuquoy L, Dharancy S, Nutten S, Pettersson S, Auwerx J, Desreumaux P: Role of peroxisome proliferator-activated receptor gamma and retinoid X receptor heterodimer in hepatogastroenterological diseases. Lancet 2002; 360:1410-1418.
7. Dubuquoy L, Rousseaux C, Thuru X, Peyrin-Biroulet L, Romano O, Chavatte P, Chamaillard M, Desreumaux P: PPARgamma as a new therapeutic target in inflammatory bowel diseases. Gut 2006; 55:1341-1349.
8. Kornbluth A, Sachar DB: Ulcerative colitis practice guideline in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2004; 99:1371-1385.
9. Fajas L, Auboeuf D, Raspe E, Schoonjans K, Lefebvre AM, Saladin R, Najib J, Laville M, Fruchart JC, Deeb S, Vidal-Puig A, Flier J, Briggs MR, Staels B, Vidal H, Auwerx J: The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem 1997; 272:18779-18789.
10. Dubuquoy L, Jansson EA, Deeb S, Rakotobe S, Karoui M, Colombel JF, Auwerx J, Pettersson S, Desreumaux P: Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis. Gastroenterology 2003; 124:1265-1276.
11. Sanchez-Hidalgo M, Martin AR, Villegas I, Alarcon De La Lastra C: Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, reduces chronic colonic inflammation in rats. Biochem Pharmacol 2005; 69:1733-1744.
12. Schaefer KL, Denevich S, Ma C, Cooley SR, Nakajima A, Wada K, Schlezinger J, Sherr D, Saubermann LJ: Intestinal antiinflammatory effects of thiazolidenedione peroxisome proliferator-activated receptor-gamma ligands on T helper type 1 chemokine regulation include nontranscriptional control mechanisms. Inflamm Bowel Dis 2005; 11:244-252.
13. Robertson MD, Bickerton AS, Dennis AL, Vidal H, Jewell DP, Frayn KN: Enhanced metabolic cycling in subjects after colonic resection for ulcerative colitis. J Clin Endocrinol Metab 2005; 90:2747-2754.
14. Adachi M, Kurotani R, Morimura K, Shah Y, Sanford M, Madison BB, Gumucio DL, Marin HE, Peters JM, Young HA, Gonzalez FJ: Peroxisome proliferator activated receptor gamma in colonic epithelial cells protects against experimental inflammatory bowel disease. Gut 2006; 55:1104-1113.
15. Katayama K, Wada K, Nakajima A, Mizuguchi H, Hayakawa T, Nakagawa S, Kadowaki T, Nagai R, Kamisaki Y, Blumberg RS, Mayumi T: A novel PPAR gamma gene therapy to control inflammation associated with inflammatory bowel disease in a murine model. Gastroenterology 2003; 124:1315-1324.
16. Nakajima A, Wada K, Miki H, Kubota N, Nakajima N, Terauchi Y, Ohnishi S, Saubermann LJ, Kadowaki T, Blumberg RS, Nagai R, Matsuhashi N: Endogenous PPAR gamma mediates anti-inflammatory activity in murine ischemia-reperfusion injury. Gastroenterology 2001; 120:460-469.
17. Cho J: Genetic advances in inflammatory bowel disease. Curr Treat Options Gastroenterol 2006; 9:191-200.
18. Brant SR, Shugart YY: Inflammatory bowel disease gene hunting by linkage analysis: rationale, methodology, and present status of the field. Inflamm Bowel Dis 2004; 10:300-311.
19. Duerr RH, Barmada MM, Zhang L, Achkar JP, Cho JH, Hanauer SB, Brant SR, Bayless TM, Baldassano RN, Weeks DE: Evidence for an inflammatory bowel disease locus on chromosome 3p26: linkage, transmission/disequilibrium and partitioning of linkage. Hum Mol Genet 2002; 11:2599-2606.
20. Eun CS, Han DS, Lee SH, Paik CH, Chung YW, Lee J, Hahm JS: Attenuation of colonic inflammation by PPARgamma in intestinal epithelial cells: effect on Toll-like receptor pathway. Dig Dis Sci 2006; 51:693-697.